Purple Biotech (PPBT) Interest & Investment Income (2014 - 2026)
Purple Biotech (PPBT) posted quarterly Interest & Investment Income of -$20000.0 for Q1 2026, up 62.96% year-over-year from -$12272.7 in Q1 2025, and up 74.68% quarter-over-quarter from -$79000.0 in Q4 2025.
Purple Biotech (PPBT) Interest & Investment Income (2014 - 2026) Analysis & Trends
Purple Biotech (PPBT) has reported Interest & Investment Income for 13 consecutive years, with -$20000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income rose 62.96% year-over-year to -$20000.0; the TTM figure through Mar 2026 stood at -$295000.0 (up 61.24% YoY), while the FY2025 annual figure was $424000.0, down 51.15% from the prior year.
- Interest & Investment Income improved to -$20000.0 in Q1 2026 per PPBT's latest filing, from -$79000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at -$20000.0 in Q1 2026 and bottomed at -$1.4 million in Q4 2023.
- Historically, Interest & Investment Income has averaged -$272764.7 across 5 years, with a median of -$123000.0 in 2023.
- Annual changes were most pronounced in 2023 — Interest & Investment Income plunged 396.43% — and 2025, when it jumped 82.68%.
- Purple Biotech's Interest & Investment Income stood at -$576000.0 in 2022, then tumbled by 144.44% to -$1.4 million in 2023, then surged by 67.61% to -$456000.0 in 2024, then surged by 82.68% to -$79000.0 in 2025, then soared by 74.68% to -$20000.0 in 2026.
- Business Quant data shows PPBT's Interest & Investment Income at -$20000.0 in Q1 2026, -$79000.0 in Q4 2025, and -$123000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 28.14 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 10.98 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 5.13 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 115.94 Mn |
| 10 | Purple Biotech | 133.62 | 133.62 | - | -79,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20,000.00 |
| Dec 31, 2025 | -79,000.00 |
| Sep 30, 2025 | -123,000.00 |
| Jun 30, 2025 | -73,000.00 |
| Mar 31, 2025 | -54,000.00 |
| Dec 31, 2024 | -456,000.00 |
| Sep 30, 2024 | -130,000.00 |
| Jun 30, 2024 | -121,000.00 |
| Mar 31, 2024 | -95,000.00 |
| Dec 31, 2023 | -1.41 Mn |
| Sep 30, 2023 | -708,000.00 |
| Jun 30, 2023 | -123,000.00 |
| Mar 31, 2023 | -278,000.00 |
| Dec 31, 2022 | -576,000.00 |
| Sep 30, 2022 | -248,000.00 |
| Jun 30, 2022 | -89,000.00 |
| Mar 31, 2022 | -56,000.00 |
| Dec 31, 2021 | -124,000.00 |
| Sep 30, 2021 | -68,000.00 |
| Jun 30, 2021 | -78,000.00 |